FloSpine

FloSpine

Growth Stage

We’ve Got Your Back

We’ve Got Your Back

Overview

Raised to Date: Raised: $162,093

Total Commitments ($USD)

Platform

StartEngine

Start Date

09/29/2022

Close Date

01/31/2023

Min. Goal
$9,999
Max. Goal
$1,069,996
Min. Investment

$299

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.90

Pre-Money Valuation

$47,440,958

Rolling Commitments ($USD)

Status
Funded
Reporting Date

02/04/2023

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$1,318

# of Investors

165

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2022

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2C

Margin

High

Capital Intensity

Low

Location

Boca Raton, Florida

Business Type

Growth

FloSpine, with a valuation of $47.4 million, is raising funds on StartEngine. It is a medical device company using new technology and design concepts to solve problems related to the human spinal column. The spinal implants of FloSpine are innovative, cost-effective, high-margin, and lead to shorter hospital stays and improved patient outcomes. The KeyLift device fits in between the laminar of the spine and can be inserted through a small incision. Peter Harris founded FloSpine in June 2022. The current crowdfunding campaign has a minimum target of $9,999.20 and a maximum target of $1,069,995.60. The campaign proceeds will be used to launch new products, including a 3D-printed titanium cervical cage and a KeyLift expandable inter-laminar system.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$1,557,981

$1,254,783

COGS

$470,571

$280,235

Tax

$0

$0

 

 

Net Income

$-699,753

$-166,166

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$885,057

$68,182

Accounts Receivable

$160,731

$212,113

Total Assets

$2,164,439

$1,228,098

Short-Term Debt

$105,037

$176,552

Long-Term Debt

$1,962,359

$229,998

Total Liabilities

$2,067,396

$406,550

Financials as of: 09/29/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

Back pain sucks. Even worse is making a brutal decision between getting surgery or trying alternative forms of treatment. While getting rods and screws surgically inserted into your spine will alleviate pain, it is an expensive and daunting decision. Other options, like physical therapy, spinal cord stimulators, painkillers, or other types of therapy, can be ineffective. 

Simply put, there is no intermediate option for patients who have tried alternative forms of therapy but do not want to have a full-blown surgery to insert rods and screws. 

Until now.

FloSpine, the company I’m introducing to you today, has created a revolutionary new device called the KeyLift.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
FloSpine on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $47,440,958
Price per Share: $2.90

Follow company

Follow FloSpine on StartEngine 2022

Buy FloSpine's Deal Report

Warning: according to the close date for this deal, FloSpine may no longer be accepting investments.

FloSpine Deal Report

Get KingsCrowd’s comprehensive report on FloSpine including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether FloSpine is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the FloSpine deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge